{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NMO+Spectrum+Disorder+%28NMOSD%29",
    "query": {
      "condition": "NMO Spectrum Disorder (NMOSD)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 31,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NMO+Spectrum+Disorder+%28NMOSD%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:11:06.996Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06780709",
      "title": "Impact of a Structured Wellness Behavioral Intervention on Quality of Life in NMOSD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neuromyelitis Optica Spectrum Disorder (NMOSD)"
      ],
      "interventions": [
        {
          "name": "Wellness Program and Behavioral Counseling",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-01-21",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2025-04-17",
      "last_synced_at": "2026-05-22T04:11:06.996Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06780709"
    },
    {
      "nct_id": "NCT05909761",
      "title": "Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neuromyelitis Optica Spectrum Disorder",
        "Pregnancy Related"
      ],
      "interventions": [
        {
          "name": "UPLIZNA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "15 Years and older · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2026-04-15",
      "completion_date": "2032-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-27",
      "last_synced_at": "2026-05-22T04:11:06.996Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05909761"
    },
    {
      "nct_id": "NCT04131673",
      "title": "MS and NMOSD in African-Americans",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis",
        "Neuromyelitis Optica"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Jagannadha R Avasarala",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2019-07-05",
      "completion_date": "2023-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-11-14",
      "last_synced_at": "2026-05-22T04:11:06.996Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04131673"
    },
    {
      "nct_id": "NCT05966467",
      "title": "Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neuromyelitis Optica Spectrum Disorder",
        "NMOSD",
        "AQP4+ NMOSD"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2024-02-01",
      "completion_date": "2030-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-10",
      "last_synced_at": "2026-05-22T04:11:06.996Z",
      "location_count": 6,
      "location_summary": "Washington D.C., District of Columbia • Boston, Massachusetts • Chapel Hill, North Carolina + 3 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Plano",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05966467"
    },
    {
      "nct_id": "NCT02200770",
      "title": "N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders"
      ],
      "interventions": [
        {
          "name": "Inebilizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 231,
      "start_date": "2015-04-01",
      "completion_date": "2020-11-06",
      "has_results": true,
      "last_update_posted_date": "2021-12-03",
      "last_synced_at": "2026-05-22T04:11:06.996Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Sacramento, California • San Francisco, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02200770"
    },
    {
      "nct_id": "NCT05269667",
      "title": "A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Neuromyelitis Optica Spectrum Disorder",
        "NMOSD"
      ],
      "interventions": [
        {
          "name": "Satralizumab 120 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 4,
      "start_date": "2022-08-02",
      "completion_date": "2023-10-26",
      "has_results": true,
      "last_update_posted_date": "2025-01-22",
      "last_synced_at": "2026-05-22T04:11:06.996Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05269667"
    },
    {
      "nct_id": "NCT04886492",
      "title": "CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neuromyelitis Optica Spectrum Disorder"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "CorEvitas",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 800,
      "start_date": "2021-04-28",
      "completion_date": "2099-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-09",
      "last_synced_at": "2026-05-22T04:11:06.996Z",
      "location_count": 1,
      "location_summary": "Waltham, Massachusetts",
      "locations": [
        {
          "city": "Waltham",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04886492"
    },
    {
      "nct_id": "NCT06453694",
      "title": "Efgartigimod for the Treatment of Acute Optic Neuritis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Optic Neuritis"
      ],
      "interventions": [
        {
          "name": "Efgartigimod Alfa",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Anastasia Vishnevetsky, MD, MPH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-08-12",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-05-22T04:11:06.996Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06453694"
    },
    {
      "nct_id": "NCT06180278",
      "title": "Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Neuromyelitis Optica Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Blood tests",
          "type": "OTHER"
        },
        {
          "name": "Inebilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2024-04-02",
      "completion_date": "2028-06-26",
      "has_results": false,
      "last_update_posted_date": "2025-11-21",
      "last_synced_at": "2026-05-22T04:11:06.996Z",
      "location_count": 2,
      "location_summary": "Detroit, Michigan • Houston, Texas",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06180278"
    },
    {
      "nct_id": "NCT03766347",
      "title": "Pediatric NMOSD Observational Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neuromyelitis Optica",
        "NMO Spectrum Disorder"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 100,
      "start_date": "2018-02-01",
      "completion_date": "2024-04-03",
      "has_results": false,
      "last_update_posted_date": "2024-04-10",
      "last_synced_at": "2026-05-22T04:11:06.996Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03766347"
    }
  ]
}